This is a StreetInsider.com Premium Only Page

(CRDF) – StreetInsider.com Reports

Mar 6, 2024 06:39 AM Cardiff Oncology (CRDF) PT Raised to $14 at H.C. Wainwright

Mar 1, 2024 07:31 AM Cardiff Oncology (CRDF) PT Raised to $7 at Piper Sandler

Feb 29, 2024 04:20 PM Cardiff Oncology (CRDF) Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial

Feb 29, 2024 04:11 PM Cardiff Oncology, Inc. (CRDF) Misses Q4 EPS by 66c

Jan 17, 2024 10:32 AM Cardiff Oncology (CRDF) Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 2, 2023 04:21 PM Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 6c

Sep 27, 2023 08:08 AM Costco and Zions Bancorporation fall premarket; Rivian and Mattel rise

Sep 26, 2023 04:05 PM Cardiff Oncology (CRDF) Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer

Aug 11, 2023 06:57 AM Cardiff Oncology (CRDF) PT Lowered to $12 at H.C. Wainwright

Aug 9, 2023 05:31 PM Cardiff Oncology, Inc. (CRDF) Tops Q2 EPS by 2c

May 9, 2023 06:35 AM Cardiff Oncology (CRDF) PT Lowered to $14 at H.C. Wainwright

Mar 28, 2023 08:03 AM Cardiff Oncology (CRDF) Announces First Patient Dosed in ONSEMBLE Phase 2 Trial of Onvansertib

Mar 7, 2023 06:35 AM Cardiff Oncology (CRDF) PT Raised to $15 at H.C. Wainwright

Feb 2, 2023 08:01 AM Cardiff Oncology (CRDF) Appoints Fairooz Kabbinavar as Chief Medical Officer

Sep 13, 2022 04:31 AM Cardiff Oncology (CRDF) PT Lowered to $5 at Piper Sandler

Sep 12, 2022 05:45 AM Cardiff Oncology (CRDF) Reports New Preclinical and Clinical Data from KRAS-mutated mCRC Program

Aug 29, 2022 06:18 AM Cardiff Oncology (CRDF) PT Lowered to $6 at Baird

May 31, 2022 04:13 AM Cardiff Oncology (CRDF) PT Lowered to $7 at Piper Sandler

May 9, 2022 06:24 AM Cardiff Oncology (CRDF) PT Lowered to $22 at H.C. Wainwright

Apr 13, 2022 09:15 AM Pre-Open Stock Movers 04/13: (ATRS) (SRRA) (STAB) Higher; (NSTG) (LQDA) (BBBY) Lower (more...)

Apr 12, 2022 05:37 PM After-Hours Stock Movers 04/12: (AFMD) Higher; (NSTG) (LQDA) (HLMN) Lower (more...)

Apr 12, 2022 04:00 PM Cardiff Oncology (CRDF) Announces Chief Medical Officer Departure

Apr 5, 2022 05:24 PM Cardiff Oncology (CRDF) Files Mixed Shelf

Feb 28, 2022 06:37 AM Cardiff Oncology (CRDF) PT Lowered to $21 at Piper Sandler

Feb 25, 2022 08:02 AM Cardiff Oncology (CRDF) PT Lowered to $9 at Maxim Group

Jan 19, 2022 09:12 AM Pre-Open Stock Movers 01/19: (ZGNX) (SOFI) (LPTX) Higher; (CRDF) (ADS) (CSCO)) Lower (more...)

Jan 18, 2022 06:15 PM After-Hours Stock Movers 01/18: (SOFI) (CNXC) (TGNA) Higher; (CRDF) (ADS) Lower (more...)

Jan 18, 2022 05:02 PM Cardiff Oncology (CRDF) Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and PFS

Jan 11, 2022 08:01 AM Cardiff Oncology (CRDF) Appoints Tod Smeal as Chief Scientific Officer

Jan 5, 2022 06:52 AM William Blair Starts Cardiff Oncology (CRDF) at Outperform

Dec 7, 2021 04:11 PM Baird Starts Cardiff Oncology (CRDF) at Outperform

Nov 18, 2021 07:03 AM Cardiff Oncology (CRDF) Announces $15M Equity Investment from Pfizer (PFE); Pfizer Acquires 2.4M Share at $6.22/sh

Sep 9, 2021 09:29 AM Pre-Open Stock Movers 09/09: (CURV) (CRDF) (LULU) Higher; (BASE) (SAM) (GME) Lower (more...)

Sep 9, 2021 08:53 AM Cardiff Oncology (CRDF) PT Raised to $25 at Maxim Group

Sep 8, 2021 06:12 PM After-Hours Stock Movers 09/08: (CRDF) (PRQR) (LULU) Higher; (SAM) (ABM) (GME) Lower (more...)

Sep 8, 2021 04:15 PM Cardiff Oncology (CRDF) Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

Aug 9, 2021 08:45 AM UPDATE: Maxim Group Assumes Cardiff Oncology (CRDF) at Buy

Jul 12, 2021 08:08 AM Cardiff Oncology (CRDF) Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

Jun 8, 2021 08:31 AM Cardiff Oncology (CRDF) Reports First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan & 5-FU in Pancreatic Cancer

May 10, 2021 06:51 AM Cardiff Oncology (CRDF) PT Lowered to $25 at H.C. Wainwright

Apr 12, 2021 06:01 AM Cardiff Oncology (CRDF) Reports Onvansertib Phase 1b/2 Data Demonstrates Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC

Feb 11, 2021 05:31 PM Cardiff Oncology (CRDF) Highlights Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule

Jan 26, 2021 08:11 AM Cardiff Oncology (CRDF) Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma

Jan 15, 2021 08:06 AM Cardiff Oncology (CRDF) Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

Nov 30, 2020 06:08 AM UPDATE: Cowen Starts Cardiff Oncology (CRDF) at Outperform

Oct 22, 2020 09:16 AM H.C. Wainwright Starts Cardiff Oncology (CRDF) at Buy; 'Potently Picking off Polo-Like Kinase 1'

Oct 8, 2020 04:28 AM Piper Sandler Starts Cardiff Oncology (CRDF) at Overweight

Sep 30, 2020 09:16 AM Pre-Open Stock Movers 09/30: (CTIC) (WATT) (DUK) Higher; (OAS) (FCEL) (PRGS) Lower (more...)

Sep 30, 2020 05:59 AM Cardiff Oncology (CRDF) Prices 6.5M Share Common Offering at $13.50/Sh

Sep 29, 2020 05:54 PM After-Hours Stock Movers 9/29: (CTIC) (JFIN) (CMTL) Higher; (FCEL) (PRGS) (MU) Lower (more...)